Migraine KOL Interview

  • ID: 4332687
  • Report
  • Region: Global
  • 15 Pages
  • BMT
1 of 2

The author of Migraine KOL Interview interviewed a neurologist based in the US who specializes in headache medicine to gauge his current and anticipated future use of acute and prophylactic agents in the treatment of episodic and chronic migraine.

The drugs discussed include the anti-calcitonin gene-related peptide (CGRP) receptor monoclonal antibody AMG 334 (AMGN), anti-CGRP monoclonal antibodies ALD403 (ALDR), LY2951742 (LLY) and TEV-48125 (TEVA), small molecule CGRP receptor antagonists atogepant (AGN), ubrogepant (AGN) and telcagepant (MRK), small molecule 5HT1F receptor agonist lasmiditan (CLCD), Botox (AGN), triptans Imitrex (GSK), Maxalt (MRK) and Topamax (JNJ), Treximet (PTX), Atacand (AZN) and TI-001.

Note: Product cover images may vary from those shown
2 of 2

Loading
LOADING...

3 of 2
Note: Product cover images may vary from those shown
Adroll
adroll